Zoetis Inc., the Florham-Park based animal health business that recently spun off from Pfizer Inc., is expanding its Nebraska operations.
Plans call for a 19,000 square-foot, three-story expansion of an existing production facility in Lincoln to accommodate the transfer of products from a third-party manufacturer. Zoetis' Nebraska plant makes medicines used by veterinarians and livestock producers to treat animals.
The company expects to formally break ground this summer and complete construction in 2014. Early stages of planning and construction are underway.
The addition occurs weeks after Zoetis formally opened headquarters in Florham Park, employing about 385 at its Campus Drive building. The business was previously based in Madison.
Zoetis said the expansion in Nebraska could create an additional 30 positions during peak production time. The Lincoln site, part of the company's global manufacturing network, employs 500.
Zoetis produces some of its flagship pharmaceutical products and vaccines in Lincoln, including Bovi-Shield Gold and RespiSure One for livestock, and Rimadyl for dogs. Products made there serve about 100 markets worldwide.
"We are proud of our new name Zoetis, and look forward to continuing to produce great quality medicines and vaccines for our customers," Michael Morgan, Zoetis site leader in Lincoln, said in a statement.
Zoetis employs about 9,300 worldwide in 70 countries. The company's annual revenue is estimated at $4.3 billion.
Reporter Tom Zanki is @BizTZanki on Twitter.